T cells engineered with chimeric antigen receptors (CARs) are emerging as powerful cancer immunotherapies. Remarkable efficacies have been demonstrated in treating B-cell malignancies with CAR-T cells, leading to the FDA’s first approval of gene therapy. Currently, numerous clinical trials for hematological malignancies and solid tumors are underway worldwide. Production of CAR-T cells with proper qualities is essential for CAR-T success in vivo. Here we detail optimized protocols for the generation of CAR-T cells for preclinical studies using lentiviral gene transfer, expansion of CAR-T cells in culture, detection of CAR expression, and evaluation of CAR-T cellular cytotoxicity in vitro.
CITATION STYLE
Xu, Q., Harto, H., Berahovich, R., Xu, S., Zhou, H., Golubovskaya, V., & Wu, L. (2019). Generation of CAR-T cells for cancer immunotherapy. In Methods in Molecular Biology (Vol. 1884, pp. 349–360). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8885-3_24
Mendeley helps you to discover research relevant for your work.